Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Next Challenge: Improving And Predicting Responses As CAR-T Therapies Advance

Dec 29 2017

• By Mandy Jackson

T-cells attacking cancer_1200x675

Related Content

Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah

Oct 19 2017

Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration

Dec 13 2017

Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position

Mar 02 2017

CAR-T To Go: Juno Sees JCAR017 As Safer, Suited For Outpatients

Nov 03 2017

Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval

Aug 31 2017

Related Companies

Novartis AG

Gilead Sciences, Inc.

Kite Pharma, Inc.

Dana-Farber/Harvard Cancer Center

Harvard University

Bristol Myers Squibb Company

University of Texas MD Anderson Cancer Center

Bristol Myers Squibb Company

Bluebird Bio

AstraZeneca PLC

Eli Lilly and Company

Additional Topics

ImmunoOncology Drug Safety Research & Development Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.